ABTECT-2: A randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of ABX464 once daily for induction treatment in subjects with moderately to severely active ulcerative colitis
This study is currently enrolling.
Study Purpose: This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of investigational ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to seve ...